WCCS/EADO 2016 | The success of the dabrafenib and trametinib combination in BRAF-mutated melanoma
Axel Hauschild, MD, PhD of University Hospital Schleswig-Holstein, Kiel, Germany, gives an overview of his talk on dabrafenib and trametinib for melanoma therapy held at the 2016 World Congress on Cancers of the Skin (WCCS) and the Congress of the European Association of Dermato-Oncology (EADO) in Vienna, Austria. According to Prof. Hauschild, it was great to see that a BRAF and a MEK inhibitor (dabrafenib and trametinib respectively) were better than the BRAF inhibitor (dabrafenib) alone (NCT01584648). This set a new standard of care for BRAF-mutated melanomas according to Prof. Hauschild; the response rate was a high as 70%, which is very significant. Further, the response duration was one year and progression-free surival (PFS) and overall survival (OS) were better for the combination compared to the single agent treatment (OS was 44% after three years).
Get great new content delivered to your inboxSign up